Pro 2012-010 (2011 Annual General Meeting of Jianfeng Group)
Release time:
2020-08-05
Stock Abbreviations: Jianfeng Group Stock Code: 600 66 8 No: pro 20 12 -0 10
Zhejiang Jianfeng Group Co., Ltd.
2011 Annual General Meeting Resolution Announcement
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents . |
Important Content Note:
1 , No Rejection or Modification of Proposals at this Meeting;
2 , no new proposal submitted for vote at this meeting.
1. Meeting and Attendance
The 2011 Annual Shareholders' Meeting of Zhejiang Jianfeng Group Co., Ltd. was held on-site on May 8, 2012 at Jianfeng Building, 88 Wujiang East Road, Jinhua City, Zhejiang Province. The notice of this meeting was published in "china securities journal" and "shanghai securities news" on April 10, 20 12. The meeting was convened by the board of directors of the company and presided over by Mr. Jiang Xiaomeng, chairman of the board of directors. Participating shareholders and shareholder represent 7 people, representing 55804925 shares, accounting for 16.22 of the company's total share capital. Some directors, supervisors and senior executives of the company attended the meeting, and the company's legal counsel attended and witnessed the meeting. The convening of the meeting, held in line with the company law, the articles of association of the company.
2. Proposal ReviewThis meeting deliberated and passed the following proposals by secret ballot and item by item:
, 2011 Board of Directors Work Report;
Voting Result: Agree
55804925 , accounting for 100 of the voting shares present at the meeting;
abstained from voting, accounting for 0% of the voting shares present at the meeting;voted against 0, accounting for 0% of the voting shares present at the meeting.
2, 2011 Work Report of the Board of Supervisors;
Voting Result: Agree
55804925 , accounting for 100 of the voting shares present at the meeting;
abstained from voting, accounting for 0% of the voting shares present at the meeting;voted against 0, accounting for 0% of the voting shares present at the meeting.
3, 2011 Financial Final Accounts Report;
Voting Results: Agree
55804925 votes, accounting for 100 of the voting shares present at the meeting;
0 abstentions, accounting for 0% of the voting shares present at the meeting;voted against 0, accounting for 0% of the voting shares present at the meeting.
4, 2011 Profit Distribution Plan;
Voting Results: Agree
55804925 votes, accounting for 100 of the voting shares present at the meeting;
0 abstentions, accounting for 0% of the voting shares present at the meeting;voted against 0, accounting for 0% of the voting shares present at the meeting.
5, Plan for Hiring 2012 Audit Institutions;
voting results: agreed to
55804925 votes, accounting for 100 of the voting shares present at the meeting;
abstained from voting, accounting for 0% of the voting shares present at the meeting;voted against 0, 0% of the number of voting shares present.
6, external guarantee plan;
voting result: agreed to
55804925 votes, accounting for 100 of the voting shares present at the meeting;
0 abstentions, accounting for 0% of the voting shares present at the meeting;voted against 0, accounting for 0% of the voting shares present.
7, 2011 Annual Report and its summary.
voting result: yes
55804925 votes, accounting for 100 of the voting shares present at the meeting;
0 abstentions, accounting for 0% of the voting shares present at the meeting;0 votes against, accounting for 0% of the voting shares present at the meeting.
3. Lawyer's Witness
Lawyers Chen Xiongwu and Zuo Wenhui of Zhejiang Yijian Law Firm witnessed the shareholders' meeting on the spot and issued legal opinions, believing that the convening, convening and voting procedures of the shareholders' meeting of the company, the qualifications of the participants and other related matters are in line with laws, regulations and the relevant provisions of the Articles of Association of the Company, the resolution of the general meeting of shareholders is legal and valid.
Catalogue of 4. Documents for Reference
1
, Resolution of Shareholders' General Meeting Confirmed by Signature of Participating Directors;
2, lawyer's legal opinion.
hereby announceZhejiang Jianfeng Group Co., Ltd.
Board of Directors
May 8, 2012
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page